ReviewCancers2022
Beyond N Staging in Breast Cancer: Importance of MRI and Ultrasound-based Imaging.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- The predictive value of lymph node status pre-operation by ultrasound and MRI in early and newly diagnosed breast cancer.Clinical and experimental medicine · 2026Pooled it
- Prospective comparison of [European journal of nuclear medicine and molecular imaging · 2026Trial
- Bilateral invasive lobular breast carcinoma with synchronous gastric metastasis and orbital pseudotumor mimicking metastasis: a case report.Discover oncology · 2026Article
- Right breast invasive carcinoma and contralateral left axillary abscess representing a rare dual pathology.Discover oncology · 2026Article
- Clinicopathologic features and long term prognosis of early onset gastroenteropancreatic neuroendocrine tumors.Discover oncology · 2026Article
- MRI-Based Radiomics Model for Classifying Axillary Lymph Node Burden and Disease-Free Survival in Patients With Early-Stage Breast Cancer.Journal of magnetic resonance imaging : JMRI · 2026Article
- Development of a Dual Photoacoustic-Ultrasound Imaging System: Current Status and Future Perspectives.Sensors (Basel, Switzerland) · 2026Review
- Comparison of the efficacy and safety of HLX-02 plus pertuzumab versus HLX-02 plus pyrotinib in neoadjuvant therapy for HER2-positive breast cancer.Therapeutic advances in medical oncology · 2026Article
- Perineural invasion and risk of lymph node metastasis in early-stage operable breast cancer: a large-scale propensity-matched cohort study and meta-analysis.Therapeutic advances in medical oncology · 2026Article
- Article
- A multimodal ultrasound-based model combining tumor radiomics and axillary lymph node morphologic classification for predicting axillary nodal burden in breast cancer.Frontiers in endocrinology · 2026Article
- Diagnostic Performance of Ultrasonography Compared to Cross-Sectional Imaging in Thyroid-Related Nodal Metastasis: A Retrospective Cohort Study from Saudi Arabia.Cancer management and research · 2026Article
- Evaluating the role of sentinel lymph node biopsy in cT1-2N0M0 breast cancer: a SEER-based study.Gland surgery · 2025Article
- Development and validation of nomograms of outcomes for first-line platinum-based chemotherapy for metastatic triple-negative breast cancer: patient-level analysis of five prospective clinical trials in China.Therapeutic advances in medical oncology · 2025Article
- An Intraoperative Ultrasound Evaluation of Axillary Lymph Nodes: Cassandra Predictive Models in Patients with Breast Cancer-A Multicentric Study.Medicina (Kaunas, Lithuania) · 2024Article
- Review
- MRI radiomics and biological correlations for predicting axillary lymph node burden in early-stage breast cancer.Journal of translational medicine · 2024Article
- Obesity-Associated Breast Cancer: Analysis of Risk Factors and Current Clinical Evaluation.Advances in experimental medicine and biology · 2024Review
- Article
- Diagnostics and Therapeutics in Early Stage Breast Cancer Receiving Neoadjuvant Systemic Therapy.Cancers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The correct N-staging in breast cancer is crucial to tailor treatment and stratify the prognosis. N-staging is based on the number and the localization of suspicious regional nodes on physical examination and/or imaging. Since clinical examination of the axillary cavity is associated with a high false negative rate, imaging modalities play a central role. In the presence of a T1 or T2 tumor and 0-2 suspicious nodes, on imaging at the axillary level I or II, a patient should undergo sentinel lymph node biopsy (SLNB), whereas in the presence of three or more suspicious nodes at the axillary level I or II confirmed by biopsy, they should undergo axillary lymph node dissection (ALND) or neoadjuvant chemotherapy according to a multidisciplinary approach, as well as in the case of internal mammary, supraclavicular, or level III axillary involved lymph nodes. In this scenario, radiological assessment of lymph nodes at the time of diagnosis must be accurate. False positives may preclude a sentinel lymph node in an otherwise eligible woman; in contrast, false negatives may lead to an unnecessary SLNB and the need for a second surgical procedure. In this review, we aim to describe the anatomy of the axilla and breast regional lymph node, and their diagnostic features to discriminate between normal and pathological nodes at Ultrasound (US) and Magnetic Resonance Imaging (MRI). Moreover, the technical aspects, the advantage and limitations of MRI versus US, and the possible future perspectives are also analyzed, through the analysis of the recent literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.